{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:18:57Z","timestamp":1760188737791},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2006,6,1]]},"DOI":"10.1532\/ijh97.05188","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T20:31:27Z","timestamp":1150921887000},"page":"450-453","source":"Crossref","is-referenced-by-count":5,"title":["Successful Treatment of Refractory Peripheral T-Cell Lymphoma with a Combination of Fludarabine and Cyclophosphamide"],"prefix":"10.1007","volume":"83","author":[{"given":"Masaki","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeharu","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Armitage JO, Vose JM, Linder J, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. <i>J Clin Oncol<\/i>. 1989;<b>7<\/b>:1783-1790.","DOI":"10.1200\/JCO.1989.7.12.1783"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol. 1990;<b>1<\/b>:45-50.","DOI":"10.1093\/oxfordjournals.annonc.a057673"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;<b>89<\/b>:3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997;<b>89<\/b>:4514-4520.","DOI":"10.1182\/blood.V89.12.4514"},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;<b>13<\/b>:140-149.","DOI":"10.1093\/annonc\/mdf033"},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer. 1991;<b>64<\/b>:120-123.","DOI":"10.1038\/bjc.1991.253"},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Hochster HS, Kim KM, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1992;<b>10<\/b>:28-32.","DOI":"10.1200\/JCO.1992.10.1.28"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992;<b>10<\/b>:790-794.","DOI":"10.1200\/JCO.1992.10.5.790"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol. 1993;<b>4<\/b>:575-578.","DOI":"10.1093\/oxfordjournals.annonc.a058591"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;<b>343<\/b>:1750-1757.","DOI":"10.1056\/NEJM200012143432402"},{"key":"E00011","unstructured":"Koehl U, Li L, Nowak B, et al. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal [abstract]. Proc Am Assoc Cancer Res. 1997;<b>38<\/b>:2. Abstract 10."},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S. Combination chemotherapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. <i>Br J Haematol<\/i>. 1999;<b>104<\/b>:612-613.","DOI":"10.1046\/j.1365-2141.1999.01212.x"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;<b>18<\/b>:987-994.","DOI":"10.1200\/JCO.2000.18.5.987"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;<b>96<\/b>:71-75.","DOI":"10.1182\/blood.V96.1.71"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;<b>23<\/b>:4070-4078.","DOI":"10.1200\/JCO.2005.12.516"},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Linder J, Armitage JO. Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. Hematol Oncol. 1987;<b>5<\/b>:175-187.","DOI":"10.1002\/hon.2900050304"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Lippman SM, Miller TP, Spier CM, Slymen DJ, Grogan TM. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood. 1988;<b>72<\/b>:436-441.","DOI":"10.1182\/blood.V72.2.436.bloodjournal722436"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Armitage JO, Greer JP, Levine AM, et al. Peripheral T-cell lymphoma. Cancer. 1989;<b>63<\/b>:158-163.","DOI":"10.1002\/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO;2-B"},{"key":"E00019","doi-asserted-by":"crossref","unstructured":"Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leuk Lymphoma. 1994;<b>14<\/b>:137-139.","DOI":"10.3109\/10428199409049659"},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Ong ST, Koeppen H, Larson RA, Olopade OI. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996;<b>88<\/b>:2354-2355.","DOI":"10.1182\/blood.V88.6.2354.bloodjournal8862354"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Hast R, Jacobsson B, Petrescu A, Hjalmar V. Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma. 1999;<b>34<\/b>:597-601.","DOI":"10.3109\/10428199909058489"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Tsatalas C, Margaritis D, Kaloutsi V, Martinis G, Kotsianidis I, Bourikas G. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta Haematol. 2001;<b>105<\/b>:106-108.","DOI":"10.1159\/000046545"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol. 2001;<b>144<\/b>:1010-1015.","DOI":"10.1046\/j.1365-2133.2001.04191.x"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Go RS, Gazelka H, Hogan JD, Wester SM. Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine. Ann Hematol. 2003;<b>82<\/b>:247-250.","DOI":"10.1007\/s00277-003-0638-9"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Van Den Neste E, Michaux L, Layios N, et al. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;<b>83<\/b>:356-363.","DOI":"10.1007\/s00277-004-0858-7"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Hirose Y, Fukushima T, Masaki Y, et al. Epstein-Barr virus-associated composite lymphoma composed of peripheral T-cell lymphoma and an anaplastic variant of a diffuse large B-cell type of non-Hodgkin's lymphoma and strongly expressing p53 protein. Int J Hematol. 2004;<b>79<\/b>:260-265.","DOI":"10.1532\/IJH97.03156"},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Tobinai K, Ohtsu T, Hayashi M, et al. Epstein-Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukemia-lymphoma. Leuk Res. 1991;<b>15<\/b>:837-846.","DOI":"10.1016\/0145-2126(91)90468-9"},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Borisch B, Finke J, Hennig I, et al. Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS-related lymphomas and lymphatic tissue of HIV-positive patients. J Pathol. 1992;<b>168<\/b>:229-236.","DOI":"10.1002\/path.1711680212"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993;<b>82<\/b>:619-624.","DOI":"10.1182\/blood.V82.2.619.bloodjournal822619"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.05188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T17:49:07Z","timestamp":1586972947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.05188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,6,1]]}},"alternative-id":["6516438842X3111R"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.05188","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}